Puma Biotechnology ( (PBYI) ) has released its Q2 earnings. Here is a breakdown of the information Puma Biotechnology presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative cancer treatments, with its primary product being NERLYNX®, a medication for HER2-positive breast cancer. The company recently reported its financial results for the second quarter of 2025, highlighting a notable increase in revenue and a shift from a net loss to a net income compared to the previous year.
In the second quarter of 2025, Puma Biotechnology achieved a net product revenue of $49.2 million, up from $44.4 million in the same period of 2024. The company reported a net income of $5.9 million, or $0.12 per share, a significant improvement from a net loss of $4.5 million in the second quarter of 2024. Additionally, the company saw a substantial increase in net cash provided by operating activities, reaching $14.1 million compared to $1.0 million in the previous year.
The company also reported a decrease in operating costs and expenses, which were $45.8 million for the second quarter of 2025, down from $49.3 million in the same quarter of 2024. This reduction was primarily due to lower selling, general, and administrative expenses. Research and development expenses saw a slight increase, reflecting ongoing clinical trials for alisertib, a promising cancer treatment in development.
Looking ahead, Puma Biotechnology anticipates key milestones in the coming months, including the presentation of interim data from ongoing clinical trials. The company remains optimistic about its financial outlook for the remainder of 2025, projecting continued revenue growth and positive net income, driven by the demand for NERLYNX® and advancements in its clinical development pipeline.